Clinical Risk Checklist

Start with the cardiac questions.

Published safety reports around ibogaine have raised concern about rhythm disturbance and sudden cardiac events. A review should begin with personal and family cardiac history, including fainting, palpitations, diagnosed arrhythmia, structural heart disease, unexplained sudden death, and prior abnormal ECG findings.

Ibogaine has been associated with QT prolongation, a change that can increase concern for dangerous rhythm problems in susceptible circumstances. The FDA’s discussion of QT-related rhythm risk illustrates why QTc assessment and the wider clinical context matter when a medicine or substance may affect cardiac repolarization.

• Document cardiac symptoms, diagnoses, procedures, family history, and prior ECG information.
• Obtain and interpret an ECG/QTc in a medical setting capable of addressing abnormal findings.
• Review electrolytes and consider causes of electrolyte disturbance, including vomiting, diarrhea, poor intake, and diuretic use.
• Do not treat a single reassuring result as a blanket clearance when other concerns remain.

For a broader overview of why heart rhythm, interaction, and psychiatric questions cannot be separated, the site’s ibogaine and bipolar safety primer frames the decision around uncertainty rather than promises.

Reconcile every medicine and substance.

A complete medication review should include prescribed medicines, over-the-counter products, supplements, recent substance use, and medicines that were stopped or changed recently. Particular attention belongs on QT-prolonging agents, medications with cardiac effects, and psychiatric medicines where abrupt change could itself destabilize mood or functioning.

Medication interaction review is not a do-it-yourself substitution exercise. The NCBI overview of adverse drug reactions underscores that harmful effects can arise from drug properties, dose, patient factors, and interactions together. Any potential change requires individualized medical evaluation rather than assumptions about a “safe” washout period.

• List each agent, its timing, its purpose, and any recent dose adjustment or discontinuation.
• Flag known or possible QT-relevant medicines for qualified review.
• Identify medications used for bipolar symptoms, sleep, anxiety, psychosis, seizure disorders, blood pressure, or pain.
• Consider recent alcohol or other substance exposure as part of the immediate clinical picture.

People comparing treatment claims may encounter material about ibogaine treatment centers, but venue descriptions do not replace a medication reconciliation or specialist interpretation of a personal risk profile.

Treat mood stability as a central safety issue.

For someone with bipolar disorder—or with a personal or family history that raises concern for bipolar spectrum illness or psychosis—psychiatric assessment is not secondary to physical screening. A careful review includes prior mania or hypomania, depression, mixed symptoms, psychosis, hospitalizations, recent mood episodes, current sleep disruption, suicidality, and prior reactions to psychoactive substances.

The National Institute of Mental Health overview of bipolar disorder describes the disorder as involving significant changes in mood, energy, and activity. That variability is one reason a current state, recent trajectory, and treatment history deserve professional attention before exposure to a psychoactive substance is contemplated.

• Clarify whether there has been a recent manic, hypomanic, depressive, mixed, or psychotic episode.
• Ask directly about current suicidal thoughts, intent, planning, self-harm, and available support.
• Document family history of bipolar disorder, psychosis, or severe mood instability.
• Assess sleep, agitation, impulsivity, grandiosity, racing thoughts, and changes in functioning.

Recent instability, active suicidality, psychosis, or uncertainty about the diagnosis are reasons to pause and seek specialist evaluation—not problems for a checklist to solve.

Know when not to move forward on assumptions.

Common reasons for heightened concern in published safety discussions include a history of arrhythmia or unexplained syncope, a concerning QTc or other ECG finding, structural heart disease, significant electrolyte abnormality, complex QT-relevant medication exposure, and active or recent psychiatric instability. These are not a substitute for clinical judgment, and they should not be read as a self-triage protocol.

Specialist referral is particularly important when cardiac findings or history raise uncertainty, when medication interactions are complex, or when bipolar symptoms, psychosis, suicidality, or recent mood episodes are present. The clinical description of long QT syndrome helps explain why fainting, family history, and QTc findings can be consequential signals rather than minor details.

There is also no reliable shortcut based on expected duration. Questions about how long ibogaine may last should not displace attention from longer-lasting medical, psychiatric, and interaction concerns.

Context can matter too: accounts that frame ibogaine through sport, including football-related recovery narratives, may feel persuasive without answering the cardiac and psychiatric questions relevant to an individual person.

Questions that deserve direct answers.

• Does a normal ECG remove the risk?

  No. An ECG is one part of a time-specific assessment. Medication changes, electrolyte status, underlying disease, recent substance exposure, and psychiatric instability can all change the overall risk picture.

• When is specialist referral especially important?

  Cardiology input is important where there is a concerning cardiac history, QTc concern, syncope, arrhythmia, structural disease, or complex QT-relevant medication exposure. Psychiatric input is important with bipolar disorder, psychosis, recent mood episodes, suicidality, or uncertainty about diagnosis or medication changes.

• Can a past relapse change the assessment?

  Yes. Recent return to substance use, withdrawal risk, treatment changes, and current support may all affect the clinical picture. Discussions of relapse after ibogaine should be kept separate from claims that any exposure is predictably protective.

• What if a person is considering travel for treatment?

  Travel does not reduce the need for individualized assessment. Information about an ibogaine clinic in Mexico or treatment options in California cannot establish that exposure is appropriate for a particular cardiac or psychiatric history.

For the site’s evidence-first purpose and scope, see the independent resource’s stated approach. Its service pages also explain the limits of the information tools offered here; neither replaces medical care.